+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 51 Pages
  • July 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5645038
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Glial Cell Line Derived Neurotrophic Factor - Drugs In Development, 2022, outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Glial -derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors. It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons. The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 1 and 9 respectively. Similarly, the universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Ophthalmology and Cardiovascular which include indications Parkinson's Disease, Amyotrophic Lateral Sclerosis, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Neuropathic Pain (Neuralgia), Epilepsy, Glaucoma, Ischemic Stroke, Keratitis, Keratoconjunctivitis Sicca (Dry Eye), Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), Neurodegenerative Diseases, Peripheral Nerve Injury, Radiculopathy, Retinitis Pigmentosa (Retinitis) and Unspecified Ophthalmological Disorders.

Furthermore, this report also reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)
  • The report reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Introduction
  • Report Coverage
  • Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Overview
  • Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Companies Involved in Therapeutics Development
  • Asklepios BioPharmaceutical Inc
  • Biogen Inc
  • Copernicus Therapeutics Inc
  • Eli Lilly and Co
  • Kai Nuo Bio Sci Co Ltd
  • Kolon Life Science Inc
  • Lauren Sciences LLC
  • Neuroptika Inc
  • Sinfonia Biotherapeutics Inc
  • Stem Cell Medicine Ltd
  • Treeway BV
  • UniQure NV
  • Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drug Profiles
  • AMT-090 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Drugs for Neurodegenerative Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • EpiRepair - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Fusion Protein to Activate GDNF for Brain Ischemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Gene Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis and Retinitis Pigmentosa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Gene Therapy to Activate GDNF for Multiple System Atrophy and Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Gene Therapy to Activate GDNF for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • KLS-2031 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • LAUR-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • LAUR-301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • NRO-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Protein to Activate GDNF for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ST-502 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Stem Cell Therapy to Activate BDNF, GDNF, IGF1 and VEGF for Peripheral Nerve Injury and Neuropathic Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • TW-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Dormant Products
  • Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Product Development Milestones
  • Featured News & Press Releases
  • Jun 18, 2021: CIRM Board approves new clinical trial for ALS
  • Aug 17, 2020: Neuroptika completes enrollment in phase 2 clinical trial for Dry Eye Disease
  • Apr 27, 2020: Kolon Life Sciences launches follow-up pipeline to administer the first patient in the US
  • Jan 17, 2020: Neuroptika enrols first patient for dry eye disease trial
  • Apr 30, 2019: Neuroptika announces positive data from NRO-1 phase 1 clinical trial
  • Mar 11, 2019: Kolon gets FDA nod for testing gene therapy for neuropathic pain
  • Dec 26, 2018: Neuroptika, Spun Out from Senju Pharmaceutical launches to develop novel regenerative treatment
  • Dec 26, 2018: Neuroptika, spun out from Senju Pharmaceutical launches to develop novel regenerative treatment
  • Oct 20, 2016: Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients
  • Apr 19, 2016: Lauren Sciences awarded second grant for LAUR-301 from The ALS Association
  • Dec 13, 2010: Sangamo Announces Publication Of Data From Program To Develop ZFP Therapeutic For Parkinson's Disease In Journal Of Neuroscience.
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development by Stage of Development, 2022
  • Number of Products under Development by Therapy Areas, 2022
  • Number of Products under Development by Indication, 2022
  • Number of Products under Development by Companies, 2022
  • Products under Development by Companies, 2022
  • Number of Products under Investigation by Universities/Institutes, 2022
  • Products under Investigation by Universities/Institutes, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Pipeline by Asklepios BioPharmaceutical Inc, 2022
  • Pipeline by Biogen Inc, 2022
  • Pipeline by Copernicus Therapeutics Inc, 2022
  • Pipeline by Eli Lilly and Co, 2022
  • Pipeline by Kai Nuo Bio Sci Co Ltd, 2022
  • Pipeline by Kolon Life Science Inc, 2022
  • Pipeline by Lauren Sciences LLC, 2022
  • Pipeline by Neuroptika Inc, 2022
  • Pipeline by Sinfonia Biotherapeutics Inc, 2022
  • Pipeline by Stem Cell Medicine Ltd, 2022
  • Pipeline by Treeway BV, 2022
  • Pipeline by UniQure NV, 2022
  • Dormant Projects, 2022

List of Figures
  • Number of Products under Development by Stage of Development, 2022
  • Number of Products under Development by Therapy Areas, 2022
  • Number of Products under Development by Top 10 Indications, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Asklepios BioPharmaceutical Inc
  • Biogen Inc
  • Copernicus Therapeutics Inc
  • Eli Lilly and Co
  • Kai Nuo Bio Sci Co Ltd
  • Kolon Life Science Inc
  • Lauren Sciences LLC
  • Neuroptika Inc
  • Sinfonia Biotherapeutics Inc
  • Stem Cell Medicine Ltd
  • Treeway BV
  • UniQure NV